Related references
Note: Only part of the references are listed.Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
Carlos Taxonera et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Marisa Iborra et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice
Anita Balint et al.
JOURNAL OF CROHNS & COLITIS (2016)
Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
William J. Sandborn et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Current best practice for disease activity assessment in IBD
Alissa J. Walsh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
Candace L. Beilman et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
B. Jharap et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Jean-Frederic Colombel et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
S. Ghosh et al.
VALUE IN HEALTH (2014)
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2013)
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
Orlando Garcia-Bosch et al.
JOURNAL OF CROHNS & COLITIS (2013)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: A meta-analysis
David G. Binion et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
MEDICAL PROGRESS Ulcerative Colitis
Silvio Danese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
S. Lichtiger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Systematic review: the costs of ulcerative colitis in Western countries
R. D. Cohen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease
Margaret C. Reilly et al.
CLINICAL THERAPEUTICS (2008)
Quality of life of patients with ulcerative colitis: Past, present, and future
E. Jan Irvine
INFLAMMATORY BOWEL DISEASES (2008)
The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis
P. D. R. Higgins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms
T Bernklev et al.
INFLAMMATORY BOWEL DISEASES (2005)
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
PDR Higgins et al.
GUT (2005)
Determinants of life satisfaction in inflammatory bowel disease
KH Janke et al.
INFLAMMATORY BOWEL DISEASES (2005)
Share Paper
